Treatment for Ureaplasma and Mycoplasma hominis in Acute Vaginitis
Treat this patient with doxycycline 100 mg orally twice daily for 7 days, or alternatively azithromycin 1 g orally as a single dose. 1
Rationale and Treatment Approach
The CDC STD Treatment Guidelines consistently recommend tetracyclines as first-line therapy for urogenital mycoplasma infections. While the guidelines primarily address nongonococcal urethritis (NGU) and mucopurulent cervicitis, the same organisms (Ureaplasma urealyticum and Mycoplasma hominis) are implicated, and the treatment principles apply directly to vaginitis caused by these pathogens 1, 2, 1.
Recommended Regimens:
- Doxycycline 100 mg orally twice daily for 7 days (preferred)
- Azithromycin 1 g orally as a single dose (alternative)
Doxycycline is the preferred choice because:
- It has demonstrated 100% susceptibility against Ureaplasma species in recent resistance surveillance 3
- It provides excellent coverage for both Ureaplasma and Mycoplasma hominis
- It has extensive clinical experience and proven efficacy 4, 5
- Cost-effective compared to alternatives
Azithromycin offers the advantage of single-dose therapy, which improves compliance and allows for directly observed treatment 1. However, recent data show emerging macrolide resistance, particularly in Mycoplasma hominis 3.
Alternative Regimens (if tetracyclines contraindicated):
- Erythromycin base 500 mg orally four times daily for 7 days
- Ofloxacin 300 mg orally twice daily for 7 days
- Levofloxacin 500 mg orally once daily for 7 days 1
Critical Caveats and Pitfalls
Avoid fluoroquinolones as first-line therapy. Recent resistance data show >80% resistance rates to both ofloxacin and ciprofloxacin among urogenital mycoplasmas 3. This represents a dramatic shift from older guidelines that listed these as acceptable alternatives.
Mycoplasma hominis has intrinsic resistance to macrolides in some cases. If the patient fails azithromycin therapy, consider that M. hominis may be the predominant pathogen and switch to doxycycline or clindamycin 4.
Tetracycline-resistant Ureaplasma urealyticum exists but remains uncommon. If symptoms persist after doxycycline, consider this possibility and treat with erythromycin-based regimens 1.
Essential Management Steps
Partner Management:
- All sexual partners within the preceding 60 days must be evaluated and treated 1, 2
- Partners should receive the same treatment regimen even if asymptomatic
- This prevents reinfection and breaks the transmission chain
Follow-up Instructions:
- Abstain from sexual intercourse for 7 days after initiating therapy 1
- Return for evaluation only if symptoms persist or recur after completing treatment
- Routine test-of-cure is not necessary if symptoms resolve 1
For Persistent or Recurrent Infection:
If symptoms persist after initial treatment and the patient was compliant without reexposure:
Recommended regimen for treatment failure:
- Metronidazole 2 g orally as a single dose
- PLUS
- Erythromycin base 500 mg orally four times daily for 7 days 1
This combination addresses possible Trichomonas vaginalis co-infection and tetracycline-resistant Ureaplasma.
Testing Considerations:
Also test for Chlamydia trachomatis and Neisseria gonorrhoeae before or during treatment, as co-infections are common and may require additional or modified therapy 1, 2. The presence of mycoplasmas does not exclude other sexually transmitted pathogens.
Special Populations
Pregnancy: Doxycycline is contraindicated. Use erythromycin base 500 mg orally four times daily for 7 days or azithromycin 1 g as a single dose 1.
HIV-positive patients: Use the same treatment regimens as HIV-negative patients 1.